Efficacy and tolerability of escitalopram in depressed patients with end stage renal disease: An open placebo-controlled study;Depresyonu olan son dönem böbrek yetmezliǧi hastalarında essitalopramın etkinliǧi ve tolerabilitesi: Bir açık plasebo kontrollu çalışma

Klinik Psikofarmakoloji Bulteni

Volumn 22, Issue 1, 2012, Pages 23-30

  Yazici, Aylin Ertekin ^a   Erdem, Pervin ^a   Erdem, Abdullah ^b   Yazici, Kemal ^a   Acar, Şenel Tot ^a   Başterzi, Ayşe Devrim ^a   Taşdelen, Bahar ^a  

^a MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b MERSIN STATE HOSPITAL   (Turkey)

Author keywords

End stage renal disease; Escitalopram; Major depressive disorder

Indexed keywords

ESCITALOPRAM;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; HAMILTON SCALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PSYCHOLOGICAL RATING SCALE;

EID: 84857693446     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.5455/bcp.20120215011558     Document Type: Article

References (46)

1. El Kossi M, El Nahas M. Epidemiology and pathophysiology of Chronic Kidney Disease: Natural history, risk factors and management. In Comprehensive Clinical Nephrology, Feehally J, Floege J, Johnson Rj (editors). Third ed., Philadelphia, PA: Mosby Elsevier; 2007.p.813-21.
2. Erek E, Sever MŞ, Akoglu E, Sariyar M, Bozfakioglu S, Apaydin S, et al. Cost of renal replacement therapy in Turkey. Nephrology 2004; 9(1): 33-8.
3. Egede LE. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry 2007; 29(5): 409-16
4. Kimmel PL, Peterson AR. Depression in end-stage renal disease patients treated with hemodialysis: Tools, correlates, outcomes and needs. Semin Dial 2005; 18(2): 91-7.
5. Hedayati SS, Minhajuddin AT, Toto RD, Morris DW, Rush AJ. Prevalence of Major Depressive Episode in CKD. Am J Kidney Dis 2009; 54(3): 424-32.
6. Coşkunol H, Alper Y, Akarsu D. Diyaliz hastalari{dotless}nda görülen psikiyatrik semptomlar. Ege Ti{dotless}p Dergisi 1990; 29(4): 882-6.
7. Craven JL, Rodin GM, Johnson B. The diagnosis of major depression in renal-dialysis patients. Psychosom Med 1987; 49(5): 482-92.
8. Daneker B, Kimmel PL, Ranich T. Depression and marital dissatisfaction in patients with end-stage renal disease and in their spouses. Am J Kid Dis, 2001; 38(4): 839-46.
9. Brownbridge G, Fielding DM. Factors related to psychosocial adjustment in children with end-stage renal failure. Pediatr Nephrol 1999; 13(9): 766-70.
10. Miller GE, Cohen S, Herbert TB. Pathways linking major depression and immunity in ambulatory female patients. Psychosom Med 1999; 61(6): 850-60.
11. Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A, et al. Inflammatory markers in major depression and melancholia. J Affective Disord 2001; 63(1-3): 93-102.
12. Huang TL, Lee CT. Low serum albumin and high ferritin levels in chronic hemodialysis patients with major depression. Psychiatry Res 2007; 152(2-3): 277-80.
13. Khalil AA, Frazier SK. Depressive symptoms and dietary nonadherence in patients with end-stage renal disease receiving hemodialysis: a review of quantitative evidence. Issues Ment Health Nurs 2010;31(5): 324-30.
14. Korkut Y. Hemodiyaliz Hastalari{dotless}ni{dotless}n Öznel Uyku Kaliteleri Üzerine Karşi{dotless}la ş ti{dotless}rmali{dotless} Bir Çali ma ve Uyku Kalitesini Yordayi{dotless}ci{dotless} Faktörlerin Arati{dotless}ri{dotless}lmasi{dotless}. Klinik Psikofarmakoloji Bülteni -Bulletin of Clinical Psychopharmacology 2008;18(2):105-112
15. Drayer RA, Piraino B, Reynolds CF, Houck PR, Mazumdar S, Bernardini J, et al. Characteristics of depression in hemodialysis patients: symptoms, quality of life and mortality risk. Gen Hosp Psychiatry 2006; 28(4): 306-12.
16. Kennedy SH, Craven H, Roin GM. Major depression in renal dialysis patients: an open trial of antidepressant therapy. J Clin Psychiatry 1989; 50(2): 60-3.
17. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medicarions: association with the use of tricyclic agents. Am J Med 2000; 108(1): 2-8.
18. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT, Pollock BG, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279(4): 279-91.
19. Wuerth D, Finkelstein SH, Ciarcia J, Peterson R, Kliger AS, Finkelstein FO. Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. Am J Kidney Dis 2001; 37(5): 1011-7.
20. Spigset O, Hägg S, Stegmayr B, Dahlqvist R. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol 2000; 56(9-10): 699-703.
21. Zung W. Self-Rating Depression Scale. Arch Gen Psychiatry 1965; 12(1): 63-70.
22. Williams JB. A structured interview guide for Hamilton Depression Rating Scale. Arch Gen Psychiatr 1988; 45(8): 742-7.
23. Akdemir A, Örsel S, Daǧ I, Türkçapar H, Içcan N, Özbay H Hamilton depresyon derecelendirme ölçeǧinin geçerliliǧi, güvenilirliǧi ve klinikte kullani{dotless}mi{dotless}. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996: 4: 251-9.
24. Hamilton M. The assesment of anxiety states by rating. Br J Med Psychol 1959; 32(1): 50-5.
25. Yazi;ci; MK, Demir B, Tanriverdi N, Karaaǧaoǧlu E, Yolaç P. Hamilton Anksiyete Deǧerlendirme Ölçeǧi, deǧerlendiriciler arasi{dotless} güvenilirlik ve geçerlilik çali{dotless}şmasi{dotless}. Türk Psikiyatri Dergisi 1998; 9(2): 114-7.
26. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Suppl 1987; 334(76): 1-100.
27. Chilcot J, Wellsted D, Da Silva-Gane M, Farrington K. Depression on dialysis. Nephron Clin Pract 2008; 108(4): 256-64.
28. Johnson S, Dwyer A. Patient perceived barriers to treatment of depression and anxiety in hemodialysis patients. Clin Nephrol 2008; 69(3): 201-6.
29. Sertöz ÖÖ, Elbi MH. Bedensel hastali{dotless}klarda depresyon. Klinik Psikiyatri Dergisi 2004; 7(Suppl 2): S63-S9.
30. Kalender B, Ozdemir AÇ, Yalug I, Dervisoglu E. Antidepressant treatment i{dotless}ncreases quality of life in patients with chronic renal failure. Renal Failure 2007; 29(7): 817-22.
31. Hytell J, Bogeso KP, Perregard J, Sanchez C. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm 1992; 88(2): 157-60.
32. Mørk A, Kreilgaard M, Sánchez C. In vitro and in vivo effects of escitalopram and its enantiomers on the serotonin uptake transporter. Eur Neuropsychopharmacol 2002; 12(3): 224.
33. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50(5): 345-50.
34. Wade AG, Lemming O, Hedegaard K. Escitalopram 10 mg/day is an effective and well-tolerated first-line antidepressant in primary care. Int Clin Psychopharmacol 2002; 17(3): 95-102.
35. Gorman J, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials. CNS Spect. 2002;7(4 Suppl 1):S40-S4.
36. Lepola UM, Loft H, Reiness EH. Escitalopram (10-20mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18(4): 211-7.
37. Loosman WL, Siegert CE, Korzec A, Honig A. Validity of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory for use in end-stage renal disease patients. Br J Clin Psychol 2010;49(4):507-16.
38. Ince E, Çifter İ. Uzun süreli hemodiyaliz hastalari{dotless} ile romatoid artrit tani{dotless}si{dotless} almi{dotless}ş hastalari{dotless}n ri{dotless}hsal bozukluklar açi{dotless}si{dotless}ndan karşi{dotless}laşti{dotless}ri{dotless}lmasi{dotless}. Kriz Dergisi 1995; 3(1-2): 265-9.
39. Cukor D, Coplan J, Brown C, Friedman S, Newville H, Safier M, et al. Anxiety Disorders in Adults Treated by Hemodialysis: A Single-Center Study. Am J Kidney Dis 2008; 52(1):128-36.
40. Burke W. Fixed dose study of escitalopram in the treatment of depression, Poster present at the Annual Metting of the American College of Neuropsychopharmacology (ACNP), 2000, Puerto Rico: 2000: 10-14
41. Rush J, Bose A. Escitalopram in clinical practice: results of an open-label trial in naturalistic setting. Depress Anxiety 2005; 21(1):26-32.
42. Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety 1996; 4(4): 160-8.
43. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63(4): 331-6.
44. Lepola U, Loft H, Reines EH. Escitalopram is efficacious and well tolerated for the treatment of depression in primary care. Eur Neuropsyhopharmacol 2001; 11(3): 232.
45. Rush J, Bose A. Escitalopram in clinical practice: results of an open-label trial in naturalistic setting. Depress Anxiety 2005; 21(1): 26-32.
46. Al-Hilali N, Al-Humoud HM, Ninan VT. Profiled Hemodialysis Reduced Intradialytic Symptoms. Transplant Proc 2004; 36(6): 1827-8.